News & Events February 10, 2025 Oqory to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference January 05, 2025 Oqory Corporate Presentation January 04, 2025 Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish December 30, 2024 Vincerx Pharma to merge with private antibody-drug conjugate company Oqory December 29, 2024 Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. (BIOSPACE) December 27, 2024 Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. December 24, 2024 Nonclinical Profile of the First in Human Anti-CD38 ADC STI-6129 for Treatment of Hematological Malignancies December 22, 2024 Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma December 20, 2024 Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors September 16, 2024 Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer September 15, 2024 ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
